- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00733408
Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer
Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib
Visão geral do estudo
Status
Condições
Descrição detalhada
PRIMARY OBJECTIVES:
I. Progression free survival.
SECONDARY OBJECTIVES:
I. Response rate.
II. Overall survival.
III. Safety and toxicity.
IV. Exploratory biomarkers will be assessed as potential predictors of response to treatment including: expression of epidermal growth factor receptor (EGFR) and secreted protein acidic and rich in cysteine (SPARC) in the primary tumor and changes in levels of circulating tumor cells (CTCs) and circulating endothelial cells (CECs).
OUTLINE:
INDUCTION THERAPY: Patients receive paclitaxel albumin-stabilized nanoparticle formulation intravenously (IV) on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
MAINTENANCE THERAPY: Patients achieving complete response, partial response, or stable disease after completion of induction therapy will receive bevacizumab IV over 30-90 minutes once every 14 or 21 days and erlotinib hydrochloride orally (PO) once daily (QD) in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up per physician discretion.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
Alaska
-
Anchorage, Alaska, Estados Unidos, 99508
- Anchorage Oncology Centre
-
Anchorage, Alaska, Estados Unidos, 99508
- Katmai Oncology Group
-
Anchorage, Alaska, Estados Unidos, 99508
- Providence Alaska Medical Center
-
-
Arizona
-
Yuma, Arizona, Estados Unidos, 85364
- Yuma Cancer Center
-
-
Idaho
-
Lewiston, Idaho, Estados Unidos, 83501
- Saint Joseph Regional Medical Center
-
-
Montana
-
Bozeman, Montana, Estados Unidos, 59715
- Bozeman Deaconess Hospital
-
Kalispell, Montana, Estados Unidos, 59901
- Kalispell Regional Medical Center
-
-
Oregon
-
Bend, Oregon, Estados Unidos, 97701
- Bend Memorial Clinic
-
-
Washington
-
Kennewick, Washington, Estados Unidos, 99336
- Kadlec Clinic Hematology and Oncology
-
Kirkland, Washington, Estados Unidos, 98033
- Evergreen Hospital Medical Center
-
Mount Vernon, Washington, Estados Unidos, 98273
- Skagit Valley Hospital Regional Cancer Care Center
-
Redmond, Washington, Estados Unidos, 98052
- Group Health Cooperative, Redmond
-
Seattle, Washington, Estados Unidos, 98109
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
-
Sequim, Washington, Estados Unidos, 98384
- Olympic Medical Cancer Care Center
-
Spokane, Washington, Estados Unidos, 99208
- Spokane Valley Cancer Center-Mayfair
-
Tacoma, Washington, Estados Unidos, 98405
- Multicare Medical Oncology Hematology
-
Wenatchee, Washington, Estados Unidos, 98801
- Wenatchee Valley Medical Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Have histologically confirmed invasive breast cancer that is estrogen receptor (ER) negative (=< 10%), progesterone receptor (PR) negative (=< 10%) and human epidermal growth factor receptor 2 (HER2) normal (=< 10% of cells) by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH)
- Be receiving first-line therapy for metastatic disease
- Measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST) criteria; X-rays, scans or physical examinations used for tumor measurement must have been completed within 28 days prior to registration; X-rays, scans or other tests for assessment of non-measurable disease must have been performed within 42 days prior to registration
- OR non-measurable disease only, with rising serum cancer antigen (CA)15-3 or CA 27.29 or carcinoembryonic antigen (CEA) documented by two consecutive measurements taken at least 14 days apart with the most recent measurement being within 42 days prior to registration; the second CA 15-3 or CA 27.29 or CEA value must have at least a 20% increase over the first and for CA 15-3 or CA 27.29 be greater than or equal to 40 units/mL or for CEA be greater than or equal to 4 ng/mL
- Subjects with brain metastases as their first site of disease recurrence may be eligible if treated by definitive radiation (stereotactic radiosurgery or whole brain) with clinically controlled neurologic symptoms for a period of 21 days prior to study treatment
- Bilirubin =< 1.5 mg/dL
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X upper limit of normal, unless bone metastasis is present in the absence of liver metastasis
- Alkaline phosphatase =< 2.5 X upper limit of normal, unless bone metastasis is present in the absence of liver metastasis
- Platelets > 100,000 cells/mm^3
- Hemoglobin > 9.0 g/dL
- Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
- Creatinine =< 1.5 mg/dL is recommended; however, institutional norms are acceptable
- If of childbearing potential must have a negative pregnancy test and use an effective method to avoid pregnancy for the duration of the trial and for at least 6 months after completion of study therapy
- Pre-existing peripheral neuropathy, if present, must be < grade 2 (per Common Terminology Criteria for Adverse Events [CTCAE] version 3.0)
- Patients must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional standards and federal guidelines
Exclusion Criteria:
- Recurrent disease within 12 months after completion of adjuvant chemotherapy containing a weekly taxane
- Central nervous system (CNS) metastases that are symptomatic and/or requiring steroids
- Pre-existing nephritic syndrome
- Serious intercurrent medical or psychiatric illness including serious active infection
- Inadequately controlled hypertension (defined as systolic blood pressure > 150 and/or diastolic blood pressure > 100 mmHg on antihypertensive medications)
- Any prior history of hypertensive crisis or hypertensive encephalopathy
- New York Heart Association (NYHA) grade II or greater congestive heart failure
- History of myocardial infarction or unstable angina within 6 months prior to study enrollment
- History of stroke or transient ischemic attack within 6 months prior to study enrollment
- Significant vascular disease (e.g., aortic aneurysm, aortic dissection)
- Symptomatic peripheral vascular disease
- Evidence of bleeding diathesis or coagulopathy
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study
- Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment
- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment
- Serious, non-healing wound, ulcer, or bone fracture
Proteinuria at screening as demonstrated by either:
- Urine protein:creatinine (UPC) ratio >= 1.0 at screening OR
- Urine dipstick for proteinuria > 2+ (patients discovered to have > 2+ proteinuria on dipstick urinalysis at baseline must have a UPC ratio done that is < 1.0 to be eligible; if the UPC ratio is >= 1.0 then the patient should undergo a 24-hour urine collection which must demonstrate =< 1 g of protein in 24 hours for the patient to be eligible)
- Known hypersensitivity to any component of bevacizumab or to nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Tx (chemo, MoAb, and enzyme inhibitor)
INDUCTION THERAPY: Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. MAINTENANCE THERAPY: Patients achieving complete response, partial response, or stable disease after completion of induction therapy will receive bevacizumab IV over 30-90 minutes once every 14 or 21 days and erlotinib hydrochloride PO QD in the absence of disease progression or unacceptable toxicity. |
Dado IV
Outros nomes:
Dado PO
Outros nomes:
Dado IV
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Progression-free Survival (PFS)
Prazo: Time from date of registration to date of first documentation of progression or symptomatic deterioration or death due to any cause, assessed up to 8 years
|
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Kaplan-Meier survival curves will be used.
A 95% confidence interval for the median PFS will be calculated.
A lower bound greater than 8 months would be strong evidence that Nab-Paclitaxel- bevacizumab induction therapy followed by bevacizumab-erlotinib hydrochloride maintenance therapy is superior to paclitaxel and bevacizumab.
However, a median PFS of 13 months or greater (regardless of whether the 95% confidence interval for the median extends below 8 months) could also indicate promising results.
|
Time from date of registration to date of first documentation of progression or symptomatic deterioration or death due to any cause, assessed up to 8 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Overall Survival
Prazo: Time from date of registration to date of death due to any cause, assessed up to 8 years
|
Kaplan-Meier survival curves will be used.
|
Time from date of registration to date of death due to any cause, assessed up to 8 years
|
Percentage of Participants With Response
Prazo: Up to 8 years
|
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
|
Up to 8 years
|
Incidence of Adverse Events as Assessed by National Cancer Institute CTCAE Version 3.0
Prazo: Up to 30 days after treatment discontinuation
|
Adverse events that meet severity grade 2 or greater will be collected and reported.
The number and percent of subjects reporting adverse events (all, severe or worse, serious and related) will be summarized for all patients, and stratified by center and other subgroups of interest.
|
Up to 30 days after treatment discontinuation
|
EGFR and SPARC Expression in the Primary Tumor
Prazo: Up to 8 years
|
Up to 8 years
|
|
Changes in Levels of Circulating Tumor Cells
Prazo: Baseline to up to 8 years
|
Descriptive statistics, such as mean, standard deviation, and range, will be summarized for circulating tumor cells at baseline and last visit.
|
Baseline to up to 8 years
|
Changes in Levels of Circulating Endothelial Cells
Prazo: Baseline to up to 8 years
|
Descriptive statistics, such as mean and standard deviation, will be summarized for circulating endothelial cells at baseline and last visit.
|
Baseline to up to 8 years
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças de pele
- Neoplasias
- Neoplasias por local
- Doenças da mama
- Neoplasias da Mama
- Neoplasias da Mama Triplo Negativas
- Efeitos Fisiológicos das Drogas
- Mecanismos Moleculares de Ação Farmacológica
- Inibidores Enzimáticos
- Agentes Antineoplásicos
- Fatores imunológicos
- Moduladores de Tubulina
- Agentes Antimitóticos
- Moduladores de Mitose
- Agentes Antineoplásicos Fitogênicos
- Inibidores de angiogênese
- Agentes Moduladores da Angiogênese
- Substâncias de crescimento
- Inibidores de crescimento
- Inibidores de proteína quinase
- Paclitaxel
- Anticorpos
- Cloridrato De Erlotinibe
- Imunoglobulinas
- Bevacizumabe
- Paclitaxel ligado à albumina
- Anticorpos Monoclonais
- Agentes Antineoplásicos Imunológicos
Outros números de identificação do estudo
- 6628 (Fred Hutchinson Cancer Research Center/UW Consortium)
- P30CA015704 (Concessão/Contrato do NIH dos EUA)
- NCI-2010-00041 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Câncer de Mama Estágio IV
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)ConcluídoAdenocarcinoma Intestinal Delgado | Adenocarcinoma do Intestino Delgado Estágio III AJCC v8 | Estágio IIIA Adenocarcinoma Intestinal Delgado AJCC v8 | Estágio IIIB Adenocarcinoma Intestinal Delgado AJCC v8 | Estágio IV Adenocarcinoma Intestinal Delgado AJCC v8 | Ampola de Vater Adenocarcinoma | Estágio... e outras condiçõesEstados Unidos
-
National Taiwan University HospitalDesconhecidoCâncer de cólon estágio IVTaiwan
-
Sabz BiomedicalsMinistry of Health and Medical Education; Digestive Diseases Research Institute...RecrutamentoCâncer de cólon estágio IVIrã (Republic Islâmica do Irã
-
Ohio State University Comprehensive Cancer CenterConcluídoCâncer de cólon recorrente | Câncer retal recorrente | Câncer de Bexiga Estágio IV A | Câncer retal estágio IV A | Câncer de cólon estágio IV B | Câncer retal estágio IV BEstados Unidos
-
University of UtahNational Cancer Institute (NCI)RecrutamentoFadiga | Estilo de vida sedentário | Carcinoma de Próstata Metastático | Câncer de Próstata Estágio IV AJCC (American Joint Committee on Cancer) v8 | Câncer de Próstata Estágio IVA AJCC (American Joint Committee on Cancer) v8 | Câncer de Próstata Estágio IVB AJCC (American Joint Committee on...Estados Unidos
-
City of Hope Medical CenterNational Cancer Institute (NCI)ConcluídoCâncer de cólon em estágio IV | Câncer retal estágio IV | Câncer de cólon recorrente | Câncer retal recorrenteEstados Unidos
-
National Cancer Institute (NCI)ConcluídoCâncer de cólon em estágio IV | Câncer retal estágio IV | Câncer de cólon recorrente | Câncer retal recorrenteEstados Unidos
-
National Cancer Institute (NCI)ConcluídoCâncer de cólon em estágio IV | Câncer retal estágio IV | Câncer de cólon recorrente | Câncer retal recorrenteCanadá
-
National Cancer Institute (NCI)ConcluídoCâncer de cólon em estágio IV | Câncer retal estágio IV | Câncer de cólon recorrente | Câncer retal recorrenteEstados Unidos
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)ConcluídoCâncer de cólon em estágio IV | Câncer retal estágio IV | Câncer de cólon recorrente | Câncer retal recorrenteEstados Unidos
Ensaios clínicos em bevacizumabe
-
Centre Hospitalier Universitaire de NiceRescindido
-
Hospital Universitari de BellvitgeInstituto de Salud Carlos IIIRescindidoCâncer de cólon | Metástase irressecável originária de câncer de cólonEspanha
-
Neon HospitalOndokuz Mayıs UniversityConcluídoEdema macular diabético
-
Istituto Scientifico Romagnolo per lo Studio e...ConcluídoCâncer Colorretal MetastáticoItália
-
West China HospitalRecrutamentoNeoplasia do EstômagoChina
-
The Ludwig Boltzmann Institute of Retinology and...Concluído
-
Northwell HealthConcluídoGlioblastoma multiforme | Astrocitoma AnaplásicoEstados Unidos
-
University of California, San DiegoRescindido
-
University of NottinghamDesconhecidoNeovascularização da Córnea
-
Shahid Beheshti University of Medical SciencesDesconhecidoDoença retinovascularIrã (Republic Islâmica do Irã